SCHEMBL5872072

SCHEMBL5872072

CCn1c(=O)cc(O)c2cccnc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.60
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
COMT P21964 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
FEN1 P39748 1/20 0.41
PKM P14618 1/20 0.41
SRC P12931 1/20 0.41
IDO1 P14902 1/20 0.40
NPC1 O15118 1/20 0.40
ALOX12 P18054 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872017 0.90 ALDH1A1 (0.51) KDM4ECCNA2CDK2ALDH1A1MEN1
SCHEMBL1523205 0.87 ALDH1A1 (0.63) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL23443327 0.84 KDM4E (0.45) KDM4ECCNA2CDK2ALDH1A1MEN1
SCHEMBL1523271 0.83 RXFP1 (0.51) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL11160946 0.83 KDM4E (0.44) KDM4ECCNA2CDK2ALDH1A1MEN1
SCHEMBL23410326 0.83 KDM4E (0.44) KDM4ECCNA2CDK2ALDH1A1MEN1
SCHEMBL829931 0.82 MEN1 (0.63) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL5871967 0.81 FEN1 (0.54) KDM4EALDH1A1KMT2AMAPTCOMT
SCHEMBL8691517 0.80 HSD17B10 (0.46) KDM4ECCNA2CDK2ALDH1A1MEN1
SCHEMBL5871817 0.79 MAPT (0.61) KDM4EALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 KDM4E 4050/4885CCNA2 1725/4885CDK2 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.